Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study

Reuters03-05

Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study

Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03 (AK104-201) study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603042126PR_NEWS_USPR_____CN02053) on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617993975?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617993975","market":"nz","top_or_hot":-1,"title":"Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03 (AK104-201) study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603042126PR_NEWS_USPR_____CN02053) on March 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 10:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03 (AK104-201) study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603042126PR_NEWS_USPR_____CN02053) on March 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0540923850.HKD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1f0Gzd:1","article_id":"2617993975","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617993975","pubTimestamp":1772677611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03  study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1574":"生物医药B类股","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","09926":"康方生物","BK1161":"生物科技","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC"},"translate_title":"康方生物报告在II期宫颈癌研究中，卡多尼单抗完全缓解者的24个月总生存率为100%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study\n    \n\n        Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03 (AK104-201) study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603042126PR_NEWS_USPR_____CN02053) on March 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617993975","isCrawlerRequest":true}